Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 103.19M | 65.24M | 41.44M | 29.16M | 22.16M |
Gross Profit | 97.71M | 19.33M | 16.23M | 7.83M | 5.01M |
EBITDA | 4.05M | -2.71M | 658.24K | -3.41M | -3.27M |
Net Income | 5.26M | -4.92M | -1.19M | -4.61M | -4.19M |
Balance Sheet | |||||
Total Assets | 108.72M | 92.62M | 34.97M | 38.34M | 37.86M |
Cash, Cash Equivalents and Short-Term Investments | 45.96M | 46.90M | 6.15M | 7.74M | 11.70M |
Total Debt | 15.38M | 16.04M | 10.99M | 10.00M | 10.03M |
Total Liabilities | 36.60M | 27.24M | 17.26M | 15.99M | 14.04M |
Stockholders Equity | 72.12M | 65.38M | 17.72M | 22.35M | 23.81M |
Cash Flow | |||||
Free Cash Flow | 786.00K | -7.46M | -2.55M | -3.82M | -9.27M |
Operating Cash Flow | 3.68M | -5.93M | -2.06M | -248.74K | -402.56K |
Investing Cash Flow | -1.49M | -1.53M | 5.86M | -3.57M | -8.87M |
Financing Cash Flow | -3.17M | 48.06M | -5.39M | -70.37K | 7.03M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
59 Neutral | $887.73M | 149.42 | 8.30% | ― | 39.19% | 273.91% | |
52 Neutral | $7.61B | 0.10 | -63.03% | 2.08% | 16.34% | 0.32% | |
― | $98.22M | ― | -15.86% | ― | ― | ― | |
61 Neutral | AU$193.22M | ― | -4.06% | ― | 20.36% | 64.81% | |
49 Neutral | AU$148.37M | ― | -58.61% | ― | ― | -74.88% | |
45 Neutral | AU$117.81M | ― | -35.20% | ― | 4.68% | -155.42% | |
41 Neutral | AU$116.39M | ― | -52.37% | ― | 471.29% | -4.58% |
PolyNovo announced a special briefing featuring Professor Toby Coates, who successfully used PolyNovo’s NovoSorb BTM in a groundbreaking islet cell transplant for a Type 1 diabetic patient. This development highlights NovoSorb’s versatility and potential to enter new markets, reinforcing PolyNovo’s innovative position in the medical technology industry.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo announced a special briefing hosted by Bell Potter featuring Professor Toby Coates, who successfully used PolyNovo’s NovoSorb in a pancreatic islet transplant for a long-term Type 1 diabetic. This marks a new market entry for NovoSorb, showcasing its versatility and potential impact on the medical field, particularly in islet cell transplantation.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
Polynovo Limited has announced a significant change in its shareholder structure, with various entities, including State Street Bank and Trust Company and its subsidiaries, becoming substantial holders. This development indicates a shift in the company’s ownership dynamics, potentially impacting its strategic decisions and market positioning. The involvement of major financial institutions as substantial holders could influence Polynovo’s future operations and stakeholder engagements.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo has released a recording of its May 2025 Investor Update Webcast for shareholders and interested parties who missed the live event. This announcement underscores PolyNovo’s commitment to transparency and stakeholder engagement, potentially strengthening its market position and investor relations.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo announced positive results from a ‘first in human’ study using its NovoSorb BTM technology for cell therapies in treating Type 1 diabetes. The study, presented by Professor Toby Coates, demonstrated the survival and function of human pancreatic islets transplanted into a new site within the skin, offering a promising alternative to the current standard of care. This breakthrough suggests significant potential for NovoSorb in the cell therapy market, potentially creating a new business segment for PolyNovo. The company is in discussions to accelerate research and development in this space, which is projected to reach USD $34 billion by 2034.
The most recent analyst rating on (AU:PNV) stock is a Buy with a A$2.50 price target. To see the full list of analyst forecasts on Polynovo stock, see the AU:PNV Stock Forecast page.
PolyNovo Limited has achieved a significant commercial milestone with the Therapeutic Goods Administration (TGA) clearance of its NovoSorb MTX (4 mm and 6 mm) products in Australia. This clearance allows the products to be marketed and sold, providing healthcare professionals with versatile options for managing soft tissue defects. The NovoSorb MTX is designed to support natural wound healing, particularly for highly exudative wounds or those with uneven wound beds, and addresses clinician demand for products without a sealing membrane. This development enhances PolyNovo’s industry positioning by expanding its product offerings and meeting the needs of plastic surgeons and other healthcare providers.
PolyNovo Limited’s presentation at the Macquarie Australia Conference highlights the company’s ongoing commitment to innovation in wound care technology. While the presentation includes forward-looking statements subject to change, it underscores the company’s strategic focus on expanding its market presence and enhancing its product offerings, which could have significant implications for its stakeholders.
PolyNovo Limited announced an upcoming investor update webcast scheduled for May 16, where it will discuss its financial performance, future outlook, cash and capital adequacy, and growth strategies, including market expansion into China and Japan and the launch of NovoSorb MTX. This update is significant for stakeholders as it highlights PolyNovo’s strategic initiatives to enhance its market position and expand its product offerings, potentially impacting its operations and industry standing.